open access

Vol 85, No 6 (2014)
ARTICLES
Get Citation

VEGF – targeted therapy for the treatment of cervical cancer – literature review

Magdalena Salomon-Pierzyńska, Beata Rembielak-Stawecka, Bogdan Michalski, Aleksander Perzyński, Violetta Skrzypulec-Plinta
DOI: 10.17772/gp/1754
·
Ginekol Pol 2014;85(6).

open access

Vol 85, No 6 (2014)
ARTICLES

Abstract

Cervical cancer is the third most common malignancy and the fourth leading cause of cancer-related death among women worldwide. Advances in the knowledge about molecular mechanisms of carcinogenesis have created opportunities for greater use of targeted therapies in contemporary oncology. In view of the unsatisfactory results of advanced cervical cancer treatment and a well-documented role of the vascular endothelial growth factor (VEGF) family members in pathogenesis and progression of cervical cancer, the use of VEGF-targeted therapy in the treatment of cervical cancer offers interesting possibilities. The efficacy of bevacizumab, a monoclonal antibody neutralizing VEGF-A in the treatment of cervical cancer, was first suggested in 2006 by a small retrospective analysis and confirmed in several Phase II clinical trials. Preliminary results of the randomized phase III studies presented at this year’s ASCO (American Society of Clinical Oncology) conference shed new light on the role of VEGF-targeted therapy in the treatment of cervical cancer, as they demonstrated that addition of bevacizumab to chemotherapy is associated with significantly improved overall survival in the group of patients with persistent, recurrent or metastatic cervical cancer.

Abstract

Cervical cancer is the third most common malignancy and the fourth leading cause of cancer-related death among women worldwide. Advances in the knowledge about molecular mechanisms of carcinogenesis have created opportunities for greater use of targeted therapies in contemporary oncology. In view of the unsatisfactory results of advanced cervical cancer treatment and a well-documented role of the vascular endothelial growth factor (VEGF) family members in pathogenesis and progression of cervical cancer, the use of VEGF-targeted therapy in the treatment of cervical cancer offers interesting possibilities. The efficacy of bevacizumab, a monoclonal antibody neutralizing VEGF-A in the treatment of cervical cancer, was first suggested in 2006 by a small retrospective analysis and confirmed in several Phase II clinical trials. Preliminary results of the randomized phase III studies presented at this year’s ASCO (American Society of Clinical Oncology) conference shed new light on the role of VEGF-targeted therapy in the treatment of cervical cancer, as they demonstrated that addition of bevacizumab to chemotherapy is associated with significantly improved overall survival in the group of patients with persistent, recurrent or metastatic cervical cancer.
Get Citation

Keywords

bevacizumab, cervical cancer, molecular targeted therap, VEGF

About this article
Title

VEGF – targeted therapy for the treatment of cervical cancer – literature review

Journal

Ginekologia Polska

Issue

Vol 85, No 6 (2014)

DOI

10.17772/gp/1754

Bibliographic record

Ginekol Pol 2014;85(6).

Keywords

bevacizumab
cervical cancer
molecular targeted therap
VEGF

Authors

Magdalena Salomon-Pierzyńska
Beata Rembielak-Stawecka
Bogdan Michalski
Aleksander Perzyński
Violetta Skrzypulec-Plinta

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl